[Therapeutic examination of efficiency for vaccine desensitization with grass pollen catalet].
The results of a 5-year studies on the therapeutical efficiency of Catalet--desensitization vaccine containing grass pollen antigens adsorbed on aluminium hydroxide--are discussed. Catalet vaccine is manufactured by Sera and Vaccines Works in Kraków in the doses of 25 PNU/ml, 250 PNU/ml, 2500 PNU/ml, and 10,000 PNU/ml. It was found that Catalet possesses a strong antigenic properties and enables complete or partial intensivity to grass pollens in the majority of treated patients. Therapeutical efficiency of Catalet has markedly been different than that of placebo, and had expressed fully following a two- or three-year treatment.
Romański
B
B
Katedry i Kliniki Alergologii i Chorób Wewnetrznych AM, Bydgoszczy.
Gawrońska-Ukleja
E
E
Pawlik
K
K
D000293:Adolescent; D000328:Adult; D003888:Desensitization, Immunologic; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D011058:Pollen / Q000276:immunology*; D006255:Rhinitis, Allergic, Seasonal / Q000517:prevention & control*; D016896:Treatment Outcome; D014612:Vaccines; D014614:Vaccines, Synthetic / Q000627:therapeutic use*
D014612:Vaccines; D014614:Vaccines, Synthetic; C082987:catalet
Badania leczniczych właściwości szczepionki odczulajacej z pyłku roślin Catalet.